May 2003
Volume 44, Issue 13
ARVO Annual Meeting Abstract  |   May 2003
Ocular Bacteria From Conjunctivitis Patients: Susceptibility to Gatifloxacin and Older Fluoroquinolones
Author Affiliations & Notes
  • M. Long
    Private Practice, New Orleans, LA, United States
  • H.G. Jensen
    Clinical Research, Allergan Inc., Irvine, CA, United States
  • Allergan Gatifloxacin Study Group
    Clinical Research, Allergan Inc., Irvine, CA, United States
  • Footnotes
    Commercial Relationships  M. Long, Allergan Inc. F; H.G. Jensen, Allergan Inc. E.
Investigative Ophthalmology & Visual Science May 2003, Vol.44, 2115. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M. Long, H.G. Jensen, Allergan Gatifloxacin Study Group; Ocular Bacteria From Conjunctivitis Patients: Susceptibility to Gatifloxacin and Older Fluoroquinolones . Invest. Ophthalmol. Vis. Sci. 2003;44(13):2115.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Abstract: : Purpose:To evaluate susceptibility of ocular isolates from bacterial conjunctivitis patients to gatifloxacin, a new ophthalmic fluoroquinolone, using levofloxacin and ciprofloxacin as comparator antimicrobials. Methods:Conjunctival swabs were taken prior to any antibacterial therapy from patients diagnosed with bacterial conjunctivitis participating in a clinical trial of gatifloxacin. MICs for independent bacterial isolates from the swabs were classified using NCCLS susceptibility breakpoints. Results:All Gram-positive ocular isolates (n=170) were susceptible to gatifloxacin, except for a single strain of Staphylococcus haemolyticus which displayed intermediate resistance. In contrast, 2.9% of Gram-positive isolates were resistant to levofloxacin and 7.6% were resistant to ciprofloxacin. All isolates of Staphylococcus epidermidis (n=38), a species frequently encountered in ocular infections, were susceptible to gatifloxacin. However, 10.5% of S. epidermidis ocular isolates were resistant to levofloxacin and 15.8% to ciprofloxacin. Another 5.3% showed intermediate resistance to levofloxacin. The gatifloxacin MIC90 for S. epidermidis ocular isolates was 2.0 µg/mL, compared to 8.0 µg/mL for levofloxacin and 32 µg/mL for ciprofloxacin. For Streptococcus pneumoniae (n=30), the gatifloxacin MIC90 was 0.25 µg/mL, compared to 1.0 µg/mL for levofloxacin and ciprofloxacin. All Gram-negative isolates (n=65) were susceptible to all 3 antibacterials. Conclusions:Substantial percentages of Gram-positive species isolated from bacterial conjunctivitis patients in this study were resistant or intermediately resistant to levofloxacin and ciprofloxacin; however, the same isolates were susceptible to gatifloxacin. MIC90 values for the most commonly encountered species of Gram-positive ocular pathogens favored gatifloxacin by 4-fold to 16-fold. Compared to older fluoroquinolones, gatifloxacin displays clearly improved activity against Gram-positive ocular bacteria in vitro.

Keywords: antibiotics/antifungals/antiparasitics • clinical (human) or epidemiologic studies: tre • conjunctivitis 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.